The last 12 months has seen a staggering amount of progress in ADCs.There are now 50+ compounds in the clinic; with approval of Pfizer’s Inotuzumab Ozogamicin expected later this year. Coupled with this, there is a bulging preclinical pipeline of 92 ADCs and counting.This year’s World ADC Berlin (20-22 February) program has been designed to reflect these progressive innovations developing next-generation ADCs.Download the 2017 programme to see more details.Bringing together 49 thought leaders in the ADC field; you will hear their lessons learned, discuss new data and debate your future opportunities. Attend this conference to access intelligence on the latest improvements in developing the next generation of clinically transformative ADCs. World ADC Berlin will help transform your ADC research – today.“Clearly the leading forum in the field”NBE Therapeutics